Moreover, the absence of BCL-W had no impact on severity of malignant disease, lymphoma immune-phenotype(s), expression of other BCL-2 family members or responses to inhibitors of MCL-1 or BCL-2 + BCL-XL + BCL-W. This evidence concerns the gene BCL2L2 and lymphoma.